Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate ...

Behavioral health company Acadia Healthcare (NASDAQ:ACHC) in Q4 CY2024 as sales rose 4.2% year on year to $774.2 million.

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024 Highlights Adjusted income ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full ... at our inaugural R&D Day in June.” ...

SAN DIEGO — SAN DIEGO — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported fourth-quarter net income of $143.7 million. The San Diego-based company said it had net income of 86 cents per ...

R&D expenses in 2025 are projected to be in the ... in the third quarter of 2025. During the reported quarter, Acadia signed an exclusive worldwide license agreement with Saniona, a Denmark ...

2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a strong ...

EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for income taxes, net interest expense and ...

Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents ... Zacks Investment Research Research and development (R&D) expenses were $100.7 million, up 51% year over year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...